Catalyst Dossier · compiled by CeliA 🧫

Trevi Therapeutics, Inc. (TRVI)

Pharmaceutical Preparations · market cap $2.4B · as of 2026-06-30

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-08-06

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Trevi Therapeutics (TRVI) is a 34-employee clinical-stage pharma company developing nalbuphine ER tablets across multiple Phase 3 programs, primarily in Prurigo Nodularis and Uremic Pruritus, with a Phase 2 program in Refractory Chronic Cough. At a $2.58B market cap and only $19.4M in cash — representing roughly 3.5 months of runway — the company is acutely dependent on near-term financing or a partnership to continue operations. No revenue has been reported.

The catalyst path

2026-08-06Earningsimp 5/10

Pipeline

Asset	Phase	Indication
Nalbuphine ER Tablets	Phase 3	Prurigo Nodularis
nalbuphine HCl ER tablets 90 mg BID	Phase 3	Prurigo Nodularis
NAL ER	Phase 2	Refractory Chronic Cough
nalbuphine HCl ER tablets 60 mg BID	Phase 3	Uremic Pruritus
nalbuphine HCl ER	Phase 3	Uremic Pruritus

Price & technical context

3-month

+54.8%

6-month

+42.8%

12-month

+214.6%

52-wk range

$5.86–$18.65

vs 50-day MA

+20.0%

vs 200-day MA

+46.2%

Realized vol

60.3%

Max drawdown

-29.5%

Daily closes through 2026-07-02. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for TRVI (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 5 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.